INVESTMENT BANKING ADVISORY FOR HEALTHCARE AND TECHNOLOGY SECTORS
INVESTMENT BANKING ADVISORY FOR HEALTHCARE AND TECHNOLOGY SECTORS
At Endor, we believe core guiding principles are the cornerstones of success. Developing and growing a company requires more than an idea and a market need – it requires leadership and perseverance. We want to know you and understand what is driving your vision. And we want to do so face to face. We will listen to your story and tell you how we could help. Once engaged, we are driven by commitment and dedication to achieve and exceed our clients’ goals.
Our role as advisors is flexible depending on each circumstance. A significant amount of our work is dedicated to helping our private clients prepare their companies for a liquidity event in the short term. We have the wisdom and experience to grasp the key value drivers of our clients’ business, leverage them into a compelling package custom tailored to each segment of the relevant audience, and decisively make the case for the uppermost valuations. For our mid and long term engagements we partner with you for strategic growth and roadmap advisory, with the goal of paving a pathway toward a future liquidity event.
Our M&A and corporate advisory activities are principally in the following sectors:
Life Sciences & Healthcare
Contract Services, Diagnostics, Medical Devices, Pharmaceuticals, Research and Clinical Reagents & Instruments, Consumer Healthcare Products
Technology
Software, Digital Health
News
Eurofins Acquires bioskin
Aug. 4, 2021 – Eurofins Cosmetics & Personal Care Testing Business line is the leading provider in cosmetics suncare and personal care testing worldwide, offering the most comprehensive range of testing and clinical services from 26 state-of-the-art laboratories in Europe, North America, Asia-Pacific and Africa and unrivalled customer service. Supported by 16 clinical laboratories, Eurofins Cosmetics & Personal Care testing offers unmatched clinical capabilities and innovation worldwide.
In line with our strategy to expand our global leadership in cosmetics and personal care and to diversify our clinical testing footprint in dermatology, for medicinal products and medical devices, Eurofins announces that it has successfully completed acquisition of bioskin GmbH (“bioskin”) a full-service, dermatology-specific CRO specialising in trials for drugs, medical devices, food supplements and advanced cosmetics.
WCG Acquires Statistics Collaborative, a Biostatistical Consultancy Specializing in Pharmaceutical and Biologics Clinical Trials
Jan. 23, 2020 – WCG (WIRB-Copernicus Group), the world’s leading provider of solutions that measurably improve the quality and efficiency of clinical trials, today announced its acquisition of Statistics Collaborative, Inc. Based in Washington, DC, Statistics Collaborative has almost 30 years’ experience providing highly specialized biostatistical consulting services to developers of new drugs and biologics. While the company’s primary focus is on late-stage clinical trials, where it contributes to trial design, reporting for Data Monitoring Committees, data analysis, and consultation for FDA presentations, it also contributes to epidemiological studies, preclinical studies, and non-clinical research. Statistics Collaborative’s experience encompasses multiple therapeutic areas, including cardiovascular diseases, oncology, infectious diseases, orphan diseases, and vaccines.
CATO Research Announces Merger With SMS-Oncology
October 28, 2019 – Cato Research, LLC (CATO) announced today that it has merged with Specialized Medical Services-oncology BV (SMS-oncology) to bolster its portfolio of global solutions dedicated to supporting life science organizations with advancing drug development. The combined company will transition to the new name, CATO SMS, in the coming year.
By joining forces, CATO and SMS-oncology expand their presence across Europe and North America, deepen their oncology and regulatory expertise, and broaden their suite of services. Headquartered in Schiphol, the Netherlands, SMS-oncology is one of the few full-service contract research organizations (CROs) in the world dedicated to oncology. The boutique CRO’s deep expertise in designing and executing complex oncology and immuno-oncology trials complements CATO’s regulatory knowledge and drug development services.
MPulse Software Acquired by JDM Technology Group
MPulse Software, Inc.,announced today that it has been acquired by JDM Technology Group, a leading provider of software solutions for the global construction industry. As of April 1, 2017, MPulse Software, Inc became MPulse Software, Inc., a JDM Technology Group company.
The acquisition will position the companies to lead the maintenance management software industry in providing reliable scheduling, tracking, and reporting tools for equipment and facilities maintenance organizations. The transaction closed on March 31, 2017, after approval by the SpecTech board of directors and stockholders. GT Securities acted as financial advisor to SpecTech on the deal.
https://www.mpulsesoftware.com/MPulse-Software-acquired-by-JDM-technology-group